Key result
Electroconvulsive therapy significantly decreased plasma noradrenaline in patients with melancholic or psychotic depression, with a trend associating this fall with clinical improvement.
Why the study?
Does electroconvulsive therapy alter plasma noradrenaline levels in patients with depressive illness?
Observational
Does electroconvulsive therapy alter plasma noradrenaline levels in patients with depressive illness?
ECT decreases plasma noradrenaline in melancholic/psychotic depressive illness, which shows a trend associated with clinical improvement.
Answers are grounded in this paper and cite their sources.
ECT-linked noradrenaline shifts differ by depression subtype and may track improvement; leaves open predictive value for future trials.
BACKGROUND: Abnormalities of catecholaminergic function have been hypothesised to cause depressive illness. Plasma noradrenaline can be used as a marker of central noradrenergic activity. It is of interest to examine the change in resting plasma noradrenaline in patients with depressive illness over a course of electroconvulsive therapy (ECT) and relate this to their clinical state. METHOD: Patients referred for ECT who suffered from DSM-III-R major depressive disorder or dysthymia were recruited. Blood samples were taken before and after each treatment, during a course of ECT, to measure plasma noradrenaline and cortisol. Clinical ratings were carried out weekly during the course of ECT. RESULTS: Plasma noradrenaline fell significantly in those patients with melancholic/psychotic depressions but increased in those with non-melancholic depressive illness. There was a strong trend indicating that a fall in plasma noradrenaline was associated with improvement in depression ratings in the melancholic/psychotic patients only. CONCLUSIONS: Electroconvlusive therapy decreases plasma noradrenaline in melancholic/psychotic depressive illness and this shows a trend associated with clinical improvement.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (1997) conducted an observational in DSM-III-R major depressive disorder or dysthymia. Electroconvulsive therapy was evaluated on Change in resting plasma noradrenaline. Electroconvulsive therapy significantly decreased plasma noradrenaline in patients with melancholic or psychotic depression, with a trend associating this fall with clinical improvement.
Synapse has enriched 10 related papers. Consider them for comparative context: